Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
19 February 2015 |
Main ID: |
NCT00047645 |
Date of registration:
|
09/10/2002 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)
|
Scientific title:
|
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis |
Date of first enrolment:
|
April 2000 |
Target sample size:
|
330 |
Recruitment status: |
Completed |
URL:
|
http://clinicaltrials.gov/show/NCT00047645 |
Study type:
|
Interventional |
Study design:
|
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
|
Phase:
|
Phase 3
|
|
Countries of recruitment
|
United States
| | | | | | | |
Contacts
|
Name:
|
Javier Szwarcberg, MD |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
InterMune |
| | |
Key inclusion & exclusion criteria
|
Male or Female, 20-79 years old
Age minimum:
20 Years
Age maximum:
79 Years
Gender:
Both
|
Health Condition(s) or Problem(s) studied
|
Idiopathic Pulmonary Fibrosis
|
Intervention(s)
|
Drug: Interferon-gamma 1b
|
Primary Outcome(s)
|
Progression-free survival time
[Time Frame: 2 years]
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|